The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
2
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
3
FDA Grants Fast Track Status to SBE303 in Urothelial Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5